Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Go back to Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Evercore ISI Removes Krystal Biotech (KRYS) From Tactical Outperform List

February 26, 2024 11:26 AM EST

Evercore ISI analyst Josh Schimmer reiterated an Outperform rating and $168.00 price target on Krystal Biotech (NASDAQ: KRYS)

Removes from Tactical Outperform List.

For an analyst ratings summary and ratings history on Krystal Biotech... More